He Eye (Stock Code: 301103), HIT Welding (Stock Code: 301137) and Huarong Chemical (Stock Code: 301256) will land on ChiNext board on March 22, 2022.

He Eye is publicly offering 30.5 million shares, including 30.5 million IPO shares offered at 42.5 yuan per share and raising funds of 1,296 million yuan. The post-public-offering share capital of He Eye is 121.558824 million in total. Liaoning He Eye Hospital Group Co., Ltd. principally engages in provision of ophthalmology specialist diagnosis and treatment services and optometry services to patients with eye diseases. In 2020, its operating income reached 838 million yuan with the net profit of 100.2359 million yuan.

HIT Welding is publicly offering 45.4534 million shares, including 45.4534 million IPO shares offered at 15.37 yuan per share and raising funds of 699 million yuan. The post-public-offering share capital of HIT Welding is 181.8134 million in total. HIT Welding Industry Co., Ltd. principally engages in research and development, production and sale of various fusion welding materials. In 2020, its operating income reached 1,363 million yuan with the net profit of 79.3326 million yuan.

Huarong Chemical is publicly offering 120 million shares, including 120 million IPO shares offered at 8.05 yuan per share and raising funds of 966 million yuan. The post-public-offering share capital of Huarong Chemical is 480 million in total. Huarong Chemical Co., Ltd. principally engages in research and development, production and sales of fine potassium products such as potassium hydroxide and chlorine products such as sodium hypochlorite and hydrochloric acid. In 2020, its operating income reached 946 million yuan with the net profit of 103.2907 million yuan.